Weight-loss drugs such as Ozempic and Wegovy have already transformed the treatment of obesity and diabetes. Millions of people now use these medications to control appetite, lose weight, and improve blood sugar levels.
But researchers are beginning to ask a much bigger question: could these drugs also influence cancer?
A new study presented at the 2026 American Society of Clinical Oncology Annual Meeting suggests that GLP-1 medications may reduce the spread of several obesity-related cancers.
The findings are attracting major attention because metastatic cancer, where cancer spreads to distant organs, is one of the biggest causes of cancer deaths worldwide.
Researchers compared people taking GLP-1 medications with people taking another type of diabetes drug known as DPP-4 inhibitors, also called gliptins.
The scientists analyzed medical records from 12,112 patients stored in the TriNetX health database.
All patients had one of seven obesity-related cancers and were diagnosed at stage I, II, or III, meaning the disease had not yet become metastatic at the start of the study.
The cancers included breast cancer, lung cancer, colorectal cancer, liver cancer, prostate cancer, pancreatic cancer, and kidney cancer.
About half of the patients took GLP-1 medications after diagnosis, while the other half used gliptins.
The GLP-1 drugs included semaglutide, tirzepatide, liraglutide, dulaglutide, pramlintide, and lixisenatide.
Researchers then tracked how many people in each group later progressed to stage IV metastatic cancer.
The results showed a potentially important difference.
For lung, breast, colorectal, and liver cancers, patients taking GLP-1 drugs were significantly less likely to develop metastatic disease.
For example, only 10% of lung cancer patients using GLP-1 medications developed metastasis, compared with 22% of patients using gliptins.
In breast cancer, metastasis occurred in 10% of GLP-1 users compared with 20% of gliptin users.
For colorectal cancer, the rates were 13% versus 22%, while liver cancer showed rates of 19% versus 28%.
The researchers calculated that GLP-1 use was associated with a 38% to 50% reduction in metastatic progression risk for these four cancers.
For prostate, pancreatic, and kidney cancers, patients taking GLP-1 drugs also showed fewer cases of metastasis, but the differences were not statistically significant.
Scientists also explored whether the GLP-1 system itself may influence tumor behavior.
Some tumors contain GLP-1 receptors, structures that can respond to GLP-1 signaling.
Using information from The Cancer Genome Atlas, researchers examined whether tumors with higher GLP-1 receptor expression were linked to better patient survival.
Overall, patients with higher GLP-1 receptor levels had a 33% lower risk of death compared with patients whose tumors had low receptor expression.
Breast cancer showed the strongest relationship, with high receptor expression linked to a 45% reduction in death risk.
Researchers believe these findings may indicate that GLP-1 signaling itself could help slow tumor progression in some cancers.
Scientists are still investigating how this might work biologically.
Possible explanations include reduced inflammation, changes in tumor metabolism, improved immune system function, or direct effects on cancer cell growth.
The study also examined safety concerns.
Researchers found that rates of stomach inflammation and pancreas inflammation were similar between people taking GLP-1 drugs and those taking gliptins.
This is important because some concerns have previously been raised about possible pancreas-related risks associated with GLP-1 medications.
Lead researcher Dr. Mark David Orland from the Cleveland Clinic said the findings provide early evidence that more studies should explore the relationship between GLP-1 drugs and cancer progression.
However, researchers strongly caution that the results do not prove the drugs directly stop cancer spread.
This was an observational study using existing medical records, which means many other hidden factors may influence the results.
Randomized controlled trials will be needed before doctors can determine whether GLP-1 medications truly reduce metastatic cancer risk.
Researchers are now planning future studies to better understand the biological mechanisms involved.
If you care about cancer, please read studies that artificial sweeteners are linked to higher cancer risk, and how drinking milk affects risks of heart disease and cancer.
For more health information, please see recent studies about the best time to take vitamins to prevent heart disease, and results showing vitamin D supplements strongly reduces cancer death.
Source: American Society of Clinical Oncology Annual Meeting.
